Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence D Mayer

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaEric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 27, 2012
Effects of block copolymer properties on nanocarrier protection from in vivo clearanceSuzanne M D'Addio, Walid Saad, Steven M Ansell, et al.
Journal of Medicinal Chemistry|May 10, 2008
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugatesSteven M Ansell, Sharon A Johnstone, Paul G Tardi, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaEric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Cancer Chemotherapy and Pharmacology|May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemiasTara L Lin, Laura F Newell, Robert K Stuart, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 27, 2012
Effects of block copolymer properties on nanocarrier protection from in vivo clearanceSuzanne M D'Addio, Walid Saad, Steven M Ansell, et al.
Journal of Medicinal Chemistry|May 10, 2008
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugatesSteven M Ansell, Sharon A Johnstone, Paul G Tardi, et al.
Pageof 6